Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study
Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: theMOMENTUM Trial
Environmental Hygiene and Risk of Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis
Identification of Environmental Factors Associated with Inflammatory Bowel Disease in a Southwestern Highland Region of China: A Nested Case-Control Study
Association between Inflammatory Bowel Disease and Vitamin D Deficiency: A Systematic Review and Meta-Analysis